Scalp psoriasis, clinical presentations and therapeutic management

被引:82
|
作者
van de Kerkhof, PCM
de Hoop, D
de Korte, J
Kuipers, MV
机构
[1] Univ Nijmegen Hosp, Dept Dermatol, NL-6500 Nijmegen, Netherlands
[2] Ziekenhuis de Gelderse Vallei, Dept Dermatol, Ede, Netherlands
[3] Univ Amsterdam, Acad Med Ctr, Dept Dermatol, NL-1105 AZ Amsterdam, Netherlands
[4] Leo Pharmaceut Prod, Dept Dermatol, Weesp, Netherlands
关键词
epidemiology; calcipotriol; corticosteroids; tar; dithranol; methotrexate; acitretin; cyclosporin;
D O I
10.1159/000018026
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: The scalp is a well-known predilection site for psoriasis. Many patients indicate that scalp psoriasis is both psychologically and socially distressing. Objective: The aim of the present investigation is to provide epidemiological data on the various manifestations of scalp psoriasis, as well as on its therapeutic management. Methods: A questionnaire, targeted on scalp psoriasis, was mailed to patient subscribers of a Dutch journal on psoriasis. In total 1,023 forms were returned and evaluated. Results: Remarkably, a relatively high occurrence of facial psoriasis (25%) and nail psoriasis (40%) was recorded. The dynamics of scalp psoriasis were rather similar to psoriasis at other sites with respect to the total duration of the disease and exacerbations/remissions. In 57% of the patients, psoriasis was psychologically and socially distressing, at least occasionally. Itch and scaling proved to be the leading symptoms, in terms of frequency of occurrence as well as in terms of distress. Therefore, these parameters should be regarded as primary efficacy criteria in the treatment of scalp psoriasis. On average, most patients were seen by the dermatologist 5 times a year. The majority of prescriptions (76%) was given by the dermatologist. The application of topical corticosteroids was by far the most frequent treatment modality. To our surprise, calcipotriol was used by 28% of patients. At the time of investigation calcipotriol was only available as ointment. Tar shampoos were used by 51% of the patients, although the clinical efficacy of such a shampoo has never been demonstrated in a controlled study. A remarkable observation was the lack of instruction on the duration of treatment and the frequency of applications. In fact, 72% of the patients used topical treatments, including topical corticosteroids, for more than 8 weeks, and 42% of the patients used an intermittent schedule of a few applications per week. Conclusions: Based on the present survey, the following profile for an optimal treatment of scalp psoriasis can be constructed: (1) effective applications a few times per week; (2) either a lotion or an emulsion, and (3) safety for long-term use.
引用
收藏
页码:326 / 334
页数:9
相关论文
共 50 条
  • [1] Psoriasis of the scalp: Diagnosis and management
    Van De Kerkhof P.C.M.
    Franssen M.E.J.
    American Journal of Clinical Dermatology, 2001, 2 (3) : 159 - 165
  • [2] The management of psoriasis
    van de Kerkhof, PCM
    NETHERLANDS JOURNAL OF MEDICINE, 1998, 52 (01): : 40 - 45
  • [3] Topical Treatments for Scalp Psoriasis
    Richard B. Warren
    Benjamin C. Brown
    Christopher E. M. Griffiths
    Drugs, 2008, 68 : 2293 - 2302
  • [4] Scalp Psoriasis
    Kircik, Leon H.
    Kumar, Sandeep
    JOURNAL OF DRUGS IN DERMATOLOGY, 2010, 9 (08) : S101 - S105
  • [5] Long-term management of scalp psoriasis: perspectives from the international psoriasis council
    Kragballe, Knud
    Menter, Alan
    Lebwohl, Mark
    Tebbey, Paul W.
    van de Kerkhof, Peter C. M.
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2013, 24 (03) : 188 - 192
  • [6] A narrative review of fixed combination calcipotriol/ betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement
    Staubach, Petra
    Koerber, Andreas
    Trueeb, Ralph M.
    Mann, Caroline
    von Kiedrowski, Ralph
    DRUGS IN CONTEXT, 2024, 13
  • [7] A Study of the Safety and Efficacy of Calcipotriol and Betamethasone Dipropionate Scalp Formulation in the Long-Term Management of Scalp Psoriasis
    Luger, T. A.
    Cambazard, F.
    Larsen, F. G.
    Bourcier, M.
    Gupta, G.
    Clonier, F.
    Kidson, P.
    Shear, N. H.
    DERMATOLOGY, 2008, 217 (04) : 321 - 328
  • [8] Scalp psoriasis: Patient point of view
    Sid-Mohand, D.
    ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE, 2009, 136 : S39 - S41
  • [9] Clinical parameters associated with severity of nail psoriasis and therapeutic efficacy
    You, Zimeng
    Yang, Heli
    Ran, Yuping
    EUROPEAN JOURNAL OF DERMATOLOGY, 2020, 30 (04) : 362 - 371
  • [10] Management of psoriasis in pregnancy
    Babalola, Olubukola
    Strober, Bruce E.
    DERMATOLOGIC THERAPY, 2013, 26 (04) : 285 - 292